Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M112,190Revenue (TTM) $M39,519Net Margin (%)25.4Altman Z-Score1.9
Enterprise Value $M119,755EPS (TTM) $4.0Operating Margin %19.3Piotroski F-Score7
P/E(ttm)10.4Beneish M-Score-2.6Pre-tax Margin (%)17.2Higher ROA y-yY
Price/Book1.710-y EBITDA Growth Rate %-1.5Quick Ratio0.6Cash flow > EarningsY
Price/Sales2.85-y EBITDA Growth Rate %-4.0Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow17.0y-y EBITDA Growth Rate %4.3ROA % (ttm)9.0Higher Current Ratio y-yY
Dividend Yield %3.7PEG--ROE % (ttm)16.3Less Shares Outstanding y-yY
Payout Ratio %79.0Shares Outstanding M2,526ROIC % (ttm)8.2Gross Margin Increase y-yY

Gurus Latest Trades with SNY

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

SNY is held by these investors:



SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-53.12view
Sanofi10% Owner 2015-01-26Buy647,448$95-53.12view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-52.19view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-33.4view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67480.7view

Press Releases about SNY :

Quarterly/Annual Reports about SNY:

    News about SNY:

    Articles On GuruFocus.com
    Buffett’s Favored Foreign Stock Lanxess Nearly Touches Record High Nov 08 2017 
    Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed Nov 02 2017 
    Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active M Oct 16 2017 
    Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal S Oct 11 2017 
    Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal S Oct 11 2017 
    Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Oct 05 2017 
    Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Oct 05 2017 
    Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Modera Sep 28 2017 
    Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough interventio Sep 20 2017 
    Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Mod Sep 16 2017 
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat

    {{numOfNotice}}
    FEEDBACK